Study of CP-675,206 in Refractory Melanoma
NCT00254579
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
251
Enrollment
INDUSTRY
Sponsor class
Conditions
Refractory Melanoma
Interventions
DRUG:
CP-675,206
Sponsor
AstraZeneca